Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
Saved in:
| Title: | Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis. |
|---|---|
| Authors: | Andreozzi, Valentina (AUTHOR), Capuano, Rocco (AUTHOR), Scannapieco, Sara (AUTHOR), Barra, Francesca (AUTHOR), d'Arco, Beatrice (AUTHOR), Giordano, Caterina (AUTHOR), Caterino, Miriam (AUTHOR), De Marca, Umberto (AUTHOR), Di Filippo, Federico (AUTHOR), Di Gregorio, Maria (AUTHOR), Barone, Paolo (AUTHOR) |
| Source: | Neurological Sciences. Jun2024, Vol. 45 Issue 6, p2807-2810. 4p. |
| Subjects: | Lymphocyte count, Bariatric surgery, Lymphopenia, Multiple sclerosis, Dimethyl fumarate, Body mass index |
| Abstract: | Introduction: Lymphopenia is a known side effect of dimethyl fumarate (DMF), a disease-modifying therapy (DMT) for patients with multiple sclerosis (pwMS). A body mass index ≥ 30 kg/m2 has been identified as a protective factor; however, no data are available on lymphopenia in pwMS undergoing to weight loss due to bariatric surgery. Methods: We described two pwMS with history of bariatric surgery who started DMF as DMT. Results: The two pwMS experienced persistent lymphopenia during DMF-treatment, which was resolved after its discontinuation. Conclusions: Several mechanisms might modify DMF pharmacokinetic profiles after bariatric surgery and its bioavailability. Absolute lymphocyte count should be monitored in pwMS treated with DMF and history of bariatric surgery and weight loss. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Introduction: Lymphopenia is a known side effect of dimethyl fumarate (DMF), a disease-modifying therapy (DMT) for patients with multiple sclerosis (pwMS). A body mass index ≥ 30 kg/m2 has been identified as a protective factor; however, no data are available on lymphopenia in pwMS undergoing to weight loss due to bariatric surgery. Methods: We described two pwMS with history of bariatric surgery who started DMF as DMT. Results: The two pwMS experienced persistent lymphopenia during DMF-treatment, which was resolved after its discontinuation. Conclusions: Several mechanisms might modify DMF pharmacokinetic profiles after bariatric surgery and its bioavailability. Absolute lymphocyte count should be monitored in pwMS treated with DMF and history of bariatric surgery and weight loss. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 15901874 |
| DOI: | 10.1007/s10072-023-07283-w |
